AHA 2021 | CRAVE: Coffee Safety in Rhythm Disorders

On the one side, caffeine can increase arrythmias or interfere with sleeping, but on the other hand, it helps people feel more energetic and do more physical activity. 

AHA 2021 | CRAVE: Seguridad del café para los trastornos del ritmo

These data contribute to the evidence supporting the fact that people who present, or are at risk of presenting supra ventricular arrythmias or atrial fibrillation might not need to avoid coffee. 

The CRAVE study included 100 young volunteers with no prior arrythmia or heart disease who were instructed to modify caffeine intake habits in two-day blocks. 

Coffee intake did not increase atrial arrythmia, but slightly increased premature ventricular contractions. On the other hand, the day people were allowed to have coffee, they walked 1,000 more steps vs the day coffee was not allowed (p=0.001).

Coffee intake was defined as one standard cup of coffee or an expresso. 

There were no differences between having or not having coffee and the incidence of atrial arrythmia. Also, coffee consumption was associated to fewer supra ventricular tachycardia, but more premature ventricular contractions. 


Read also: AHA 2021 | PALACS: Posterior Left Pericardiotomy Improves Post-Procedural AF.


The day participants were allowed to have coffee, they slept mean 36 minutes less than abstinence day. 

Original Title: The coffee and real-time atrial and ventricular ectopy (CRAVE) trial.

Reference: presentado por Marcus GM durante las sesiones científicas del congreso de la AHA 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...